RCM
MACK

RA Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

RA Capital Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-14,794
Closed -$1.44M – 75
2015
Q2 		$1.44M Hold
14,794
– – 0.14% 41
2015
Q1 		$1.38M Hold
14,794
– – 0.14% 45
2014
Q4 		$1.31M Hold
14,794
– – 0.14% 39
2014
Q3 		$1.02M Buy
+14,794
New +$791K 0.12% 35

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

RA Capital Management's MACK Position: Q3 2015 in Review

RA Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2015, closing a stake of 14,794 shares — an estimated $1.44M sold.

RA Capital Management first reported a position in MACK in Q3 2014 and held it in 4 quarters. The position peaked at $1.44M in Q2 2015. 135 funds tracked by Wall St. Rank hold MACK as of Q3 2015.

  • RA Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • RA Capital Management sold 14,794 Merrimack Pharmaceuticals, Inc. shares in Q3 2015, an estimated $1.44M.
  • RA Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2014 and held it in 4 quarters.
  • RA Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $1.44M in Q2 2015.
  • 135 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2015.

Based on RA Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.